Open AccessMedicineChemistryBiology

K. Alfarouk, C. Stock, Sophie Taylor, Megan Walsh, A. Muddathir, Daniel Verduzco, A. Bashir, O. Mohammed, G. Elhassan, S. Harguindey, S. Reshkin, M. Ibrahim, C. Rauch

2015.7.15Cancer Cell International

DOI: 10.1186/s12935-015-0221-1

tlooto Summary

This work suggests a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.

Abstract

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.

Citation format

ALFAROUK, K., et al. Resistance to cancer chemotherapy: Failure in drug response from ADME to p-gp. Cancer Cell International, 2015, 15.